错配修复缺陷对阴道近距离放疗后早期子宫内膜癌预后的影响
本研究纳入198例接受辅助阴道近距离放疗的I-II期子宫内膜样癌患者,比较错配修复缺陷(dMMR)与 proficient(pMMR)患者的预后。结果显示dMMR患者3年无复发生存率(RFS)显著更低(75% vs. 96%),且在低中危和高危亚组中均一致;多因素分析中dMMR是RFS的独立不良预后因素(HR 3.774,95%CI 1.495-9.526,P=0.005),但总生存(OS)无差异。
要点
- dMMR患者接受阴道近距离放疗后3年RFS显著低于pMMR(75% vs. 96%,P=0.001)。
- dMMR在低中危和高危亚组中均与更差RFS相关(P=0.026和P=0.038)。
- dMMR是RFS的独立预后因素(HR 3.774,95%CI 1.495-9.526,P=0.005),但与OS无关。
核心结论
- 阴道近距离放疗后,dMMR患者无论风险分级(低中危或高危)均较pMMR患者RFS更差。
- 中危子宫内膜样癌的预后可能更依赖分子特征而非传统临床病理风险分类。
研究设计与样本
- 回顾性队列研究,纳入198例已知MMR状态的I-II期子宫内膜样癌患者,均接受辅助阴道近距离放疗。
主要发现
- dMMR组较pMMR组更常见高级别肿瘤(75% vs. 57%,P=0.006)、淋巴血管侵犯(40% vs. 25%,P=0.034)和高危分类(65% vs. 49%,P=0.011)。
- dMMR组3年RFS为75%,pMMR组为96%(P=0.001)。
- 低中危亚组中dMMR与pMMR的3年RFS分别为74%和100%(P=0.026);高危亚组分别为75%和91%(P=0.038)。
- 3年OS在dMMR与pMMR间无差异(98% vs. 97%,P=0.653),在高危与低中危间也无差异(97% vs. 97%,P=0.999)。
- 多因素Cox回归显示dMMR是RFS的显著预后因素(HR 3.774,95%CI 1.495-9.526,P=0.005),但对OS不显著。
临床怎么用
- 对于接受辅助阴道近距离放疗的早期子宫内膜样癌患者,dMMR状态可提示更高的复发风险,或需加强随访或考虑强化治疗。
- 风险分层应结合分子特征(如MMR状态)而非仅依赖临床病理分类。
局限性
- 回顾性研究,样本量有限(198例),可能存在选择偏倚。
- 未报告无复发生存以外的其他终点(如复发模式、治疗毒性)及多因素OS分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the impact of mismatch repair (MMR) status on prognosis among patients with high- and low-intermediate-risk endometrioid endometrial cancer (EEC) treated with vaginal brachytherapy (VBT). MATERIALS/METHODS: 198 stage I-II EEC patients with known MMR status treated with adjuvant VBT were identified. Both low-intermediate (LIR) and high-intermediate-risk (HIR) patients were included. Clinical characteristics were compared between patients with proficient and deficient mismatch repair (pMMR and dMMR) using Fisher's exact tests for categorical variables and t-tests for continuous variables. Recurrence-free survival (RFS) and overall survival (OS) were analyzed with Kaplan-Meier estimates, the log-rank test, and Cox proportional hazards regression. RESULTS: Patients with dMMR compared to pMMR were more likely to have grade 2-3 tumors (75% vs. 57%, p = 0.006), lympho-vascular invasion (40% vs. 25%, p = 0.034), and HIR classification (65% vs. 49%, p = 0.011). Three-year RFS was inferior for dMMR compared to pMMR patients (75% vs. 96%, p = 0.001). dMMR patients compared to pMMR had similarly reduced 3-year RFS within the LIR (74% vs. 100%, p = 0.026) and HIR (75% vs. 91%, p = 0.038) subgroups. Three-year OS was not different between dMMR/pMMR patients (98% vs. 97%, p = 0.653) or HIR/LIR patients (97% vs. 97%, p = 0.999). On multivariable Cox regression, dMMR status was a significant prognostic variable for RFS (HR 3.774, CI 1.495-9.526, p = 0.005), though it was not significant for OS. CONCLUSION: Following VBT, patients with dMMR have poorer RFS compared to pMMR patients regardless of HIR/LIR risk classification. The prognosis of intermediate-risk EEC patients may lie more on a continuum dependent on molecular features rather than distinct clinicopathologic risk categories.
引用
- Li JY, Park HS, Huang GS, et al. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecol Oncol. 2021. PMID: 34602287. doi:10.1016/j.ygyno.2021.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。